We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » Clinical Trials » GCP

GCP
%{topic} RSS Feed RSS

Finalized Preclinical Gene/Cellular Therapy Guidance Skips Sponsor Suggestions

November 25, 2013
Finalized guidance on preclinical considerations for gene and cellular therapies, posted Monday, reiterates the agency’s position that sponsors should focus on five objectives in preclinical trials. Read More

Risk Aversion Keeping New Drugs Off the Market, EMA Officials Warn

November 21, 2013
Today’s regulatory culture is too risk-averse when it comes to drug approvals and risks keeping promising treatments off the market, senior officials at the European Medicines Agency say. Read More

EMA to Allow More Flexible Filings For Antibiotics for Unmet Needs

November 21, 2013
The European Medicines Agency will accept premarket applications with limited data for antibiotics that target unmet needs, according to an amended guideline on developing antibacterial drugs for multidrug-resistant infections. Read More

Customizing Treatment Can Improve Patient Compliance to Trial: Study

November 21, 2013
To improve compliance in clinical trials, investigators need to find ways to accommodate individual patient needs and help trial participants understand the rationale behind protocols, an industry report says. Read More

Number of Trial Devices Should Balance Patient Risk: MHRA

November 21, 2013
Sponsors of medical device clinical trials should avoid recruiting and putting at risk an unnecessarily large number of patients, a new guidance by the UK’s Medicines and Healthcare products Regulatory Agency says. Read More

New Pathway for Limited-Use Antibiotics Needed: Woodcock

November 21, 2013
CDER Director Janet Woodcock said Nov. 15 that she supports the creation of a swift-approval pathway for antibiotics that target limited patient populations. Read More

Indian Government Proposes Ambitious Clinical Trial Oversight Reforms

November 21, 2013
Indian authorities want clinical trial sites accredited and more heavily regulated. In a new report, a panel of advisors to the Ministry of Health and Family Welfare spells out specific reforms aimed at addressing past weaknesses in the country’s clinical investigation and drug approval processes. Read More

Investigators Need to Improve Protocol, Record-Keeping Adherence: Study

November 7, 2013
Clinical investigators need to improve adherence to study protocols and maintain better records of their trials, according to findings from an FDAnews-sponsored study. Read More

Research Group Touts Risk-Based Approach to Clinical Trials

September 25, 2013
Researchers writing in the New England Journal of Medicine are calling for a more risk-based approach to regulating clinical trials and changes to regulatory systems, with the aim of removing unnecessary hurdles to medical research. Read More

EMA Clarifies ‘Triggers’ for For-Cause Versus Routine GCP Inspections

August 28, 2013
As drug sponsors make their way through the EU approval process, there are “triggers” that can help European Medicines Agency inspection coordinators determine whether a clinical trial should undergo a routine or for-cause good clinical practice inspection, an agency working group says. Determining factors include trial size, complexity and site selection. Read More

Wrong Use of Expedited Review Can Land IRBs a Warning — or Worse

June 19, 2013
The expedited review process is intended to help IRBs quickly approve low-risk and noninvasive treatments during clinical trials. Read More

Expert: Sponsor Investigators Need to Beware of Regulatory Landscape

May 22, 2013
Investigators contemplating their own clinical trials need to understand the regulatory framework of investigator-initiated studies and what it means to be a sponsor investigator before wading into the water, a legal expert says. Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Clearancestamp_gray

    FDA Clears Lymphedema Assessment Platform for Expanded Indication

  • Herontherapeutics_logo

    Health Canada Grants Priority Review for Heron’s Non-Opioid Pain Treatment

  • Fda_logo_blue_2016

    Senate Confirms Stephen Hahn as Next FDA Commissioner

  • Healthcanada_logo

    Health Canada Approves Boehringer Ingelheim’s Ofev for Systemic Sclerosis

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing